Due to the lack of reliable clinical data much of the potential found within the cannabis plant is still to be discovered. Although anecdotal evidence has shown it’s potential use in the treatment of many diseases, an intense analysis of all the constituents of cannabis is necessary to connect the dots between the plant, therapy and disease.

There is a clear need for patients to access cannabis-derived therapeutics for a number of disorders, including drug-resistant epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, chronic pain, nausea and more.

It is our ambition to provide medical-grade products, tailored to specific diseases and compliant with pharmaceutical guidelines to organizations interested in conducting clinical trials, whether at a pre-clinical level or directly in advanced clinical trials through the application of orphan drug models.